Directed share issue in Oncopeptides AB (SE) — SEK 436 million

Carnegie acted as joint bookrunner in the directed share issue of 15,061,443 new shares at a subscription price of SEK 28.92 per share. Oncopeptides is a commercial stage global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases.
July 2022.